Furthermore, in the genetic context of wild-type TP53, FOSB expression was associated with a smaller tumor size, a lower TNM stage, a higher therapeutic response, and a more positive therapeutic outcome, suggesting potential anti-tumor effects of FOSB in NSCLC carrying wild-type TP53 (Fig. 2C). The gene discussed is FOSB; the disease is neoplasm.